Lexeo Therapeutics shares are trading higher after the company announced it has finalized the SUNRISE-FA 2 pivotal trial protocol and analysis plan to support a 2028 FDA BLA filing for LX2006.

Benzinga Newsdesk www.benzinga.com Positive 94.3%

Neg 0% Neu 0% Pos 94.3%

Comments

No comments yet. Be the first!